. 2006 Dec 20;81(6):2713–2725. doi: 10.1128/JVI.01830-06

TABLE 2.

Patient characteristics: longitudinal cohort

Patient no.	Time on therapy (days)	Peripheral blood CD4⁺ T cell count (cells/μl)^a		Time off therapy (days)	Plasma HIV RNA (copy equivalents/ml)^a		Therapy^b
Patient no.	Time on therapy (days)	On therapy	Off therapy	Time off therapy (days)	On therapy	Off therapy	Therapy^b
229	>365	1,230	791	252	<50	2,185	d4T, 3TC, NEL
230	>365	822	469	97	<50	7,515	ZDV, 3TC, IND
232	>365	997	576	1,048	<50	35,114	ZDV, 3TC, NEL
236	>365	928	684	247	<50	23,637	d4T, ddI, NVP
237	>365	1,433	1,077	56	<50	139,874	ZDV, 3TC, EFV
238	>365	690	928	55	65	613	ZDV, 3TC, IND
239	>365	759	579	63	<50	136,192	TDF, 3TC, EFV
240	>365	745	362	55	<50	16,638	ZDV, 3TC, ABC, TDF, LPVr
241	>365	720	609	56	<50	9,738	3TC, FTC, TDF, EFV

Values shown were obtained at the time of apheresis.

ZDV, zidovudine; d4T, stavudine; NEL, nelfinavir; 3TC, lamivudine; IND, indinavir; LPVr, lopinavir/ritonavir; NVP, nevirapine; EFV, efavirenz; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; ABC, abacavir.